Intelligence Feed event · Macro · 2026-10-01

    Survodutide Delivers 13.1% Weight Loss in Phase III Obesity/T2D Trial

    Question

    Survodutide Delivers 13.1% Weight Loss in Phase III Obesity/T2D Trial

    Direct answer

    Topline results from the Phase III SYNCHRONIZE-2 study showed that survodutide produced up to 13.1% mean weight loss at 76 weeks in patients suffering from both obesity and type 2 diabetes, versus 3.1% for placebo. The dual agonist profile of survodutide, which co-targets glucagon and GLP-1 receptors, met secondary endpoints in HbA1c reduction, positioning the compound as a key challenger in the metabolic therapeutic class.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-01
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Survodutide Delivers 13.1% Weight Loss in Phase III Obesity/T2D Trial”, revision 1, evidence through 2026-10-01. https://marketontology.com/market-events/2026-10-01/survodutide-delivers-13-1-weight-loss-in-phase-iii-obesity-t2d-trial-b3e976

    MACRO
    Survodutide Delivers 13.1% Weight Loss in Phase III Obesity/T2D Trial
    Topline results from the Phase III SYNCHRONIZE-2 study showed that survodutide produced up to 13.1% mean weight loss at 76 weeks in patients suffering from both obesity and type 2 diabetes, versus 3.1% for placebo. The dual agonist profile of survodutide, which co-targets glucagon and GLP-1 receptors, met secondary endpoints in HbA1c reduction, positioning the compound as a key challenger in the metabolic therapeutic class.
    ZLDPY
    Impact
    83
    OCT 1
    SIG
    92%
    ZLDPY
    Survodutide Delivers 13.1% Weight Loss in Phase III Obesity/T2D Trial
    Topline results from the Phase III SYNCHRONIZE-2 study showed that survodutide produced up to 13.1% mean weight loss at 76 weeks in patients suffering from both obesity and type 2 diabetes, versus 3.1% for placebo. The dual agonist profile of survodutide, which co-targets glucagon and GLP-1 receptors, met secondary endpoints in HbA1c reduction, positioning the compound as a key challenger in the metabolic therapeutic class.
    → Phase III results support regulatory approval and commercialization prospects for survodutide.
    Impact
    Topline results from the Phase III SYNCHRONIZE-2 study showed that survodutide produced up to 13.1% mean weight loss at 76 weeks in patients suffering from both obesity and type 2 diabetes, versus 3.1% for placebo. The dual agonist profile of survodutide, which co-targets glucagon and GLP-1 receptors, met secondary endpoints in HbA1c reduction, positioning the compound as a key challenger in the metabolic therapeutic class.
    Affected
    ZLDPY
    Transmission
    Phase III results support regulatory approval and commercialization prospects for survodutide.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    ZLDPYbiopharma royalty and milestone revenue repricingUp1-5dSource explicitly confirms Zealand Pharma partner Boehringer Ingelheim achieved positive Phase III SYNCHRONIZE-2 endpoints.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month